Effectiveness of Preoperative Iron Supplementation in Major Surgical Patients With Iron Deficiency: A Prospective Observational Study.
Study Goal
To evaluate the effectiveness of routine intravenous iron in surgical patients with iron deficiency anemia (IDA) in improving hemoglobin levels and reducing transfusion rates and hospital stay.
Results Summary
Iron supplementation in IDA patients reduced postoperative red blood cell transfusion rates (31.5% vs. 42.5%) and hospital stay by 2.8 days, with intraoperative transfusion benefits observed only if iron was administered >7 days before surgery.
Population
Surgical patients with iron deficiency anemia (IDA) or iron deficiency without anemia.
Effective Dosage
Not specified
Duration
>7 days before surgery for intraoperative benefits
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
routine intravenous iron | increase | hemoglobin level | surgical patients with iron deficiency anemia (IDA) | - | effective in improving | #1 |
iron supplementation | decrease | red blood cell (RBC) transfusion during the postoperative period | iron-supplemented IDA patients | 42.5% vs 31.5% | required less | #2 |
iron supplementation | decrease | intraoperative transfusion rate | ID and IDA patients | - | reduced | #3 |
iron supplementation | decrease | hospital stay | iron-supplemented patients | 2.8 days | significantly reduced | #4 |
preoperative IDA management with intravenous iron | decrease | intraoperative RBC transfusion rate | patients | - | reducing | #5 |
iron supplementation | decrease | hospital length of stay | all preoperatively iron-supplemented IDA patients | - | reduced | #6 |
OBJECTIVE: To evaluate the effectiveness of routine intravenous iron in surgical patients with iron deficiency anemia (IDA). BACKGROUND: Anemia is the most common medical disease in the world and is an independent risk factor for morbidity and mortality. Iron deficiency (ID) is the main cause for anemia and constitutes a potentially preventable condition with great impact on surgical outcome. METHODS: In this prospective single-center observational study, surgical patients were screened for the presence of anemia and ID. Patients were assigned to 1 of 4 study groups: A- (no anemia); A-, ID+, T+ (no anemia, iron-deficient, iron supplementation); A+ (anemia); and A+, ID+, T+ (anemia, iron-deficient, iron supplementation) according to hemoglobin level, iron status, and supplementation with iron. RESULTS: Among 1728 patients, 1028 were assigned to A-; 55 to A-, ID+, T+; 461 to A+; and 184 to A+, ID+, T+. While all iron-supplemented IDA patients required less red blood cell (RBC) transfusion during the postoperative period (A+ 42.5% vs A+, ID+, T+ 31.5%), a reduced intraoperative transfusion rate was observed for ID and IDA patients only if iron was supplemented >7 days before surgery. Hospital stay was significantly reduced by 2.8 days in iron-supplemented patients (P < 0.01 comparing 13.9 ± 0.8 days for A+, ID+, T+ vs. 16.7 ± 0.7 days for A+). CONCLUSION: Preoperative IDA management with intravenous iron is effective in improving hemoglobin level, thereby reducing intraoperative RBC transfusion rate particular if iron is administrated >7 days before surgery. Hospital length of stay was reduced in all preoperatively iron-supplemented IDA patients.